Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
Find out how FDA alignment on ATH434 could shape Alterity Therapeutics’ pivotal Phase 3 path in multiple system atrophy.
Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.
Why MAIA Biotechnology’s ateganosine program is entering a decisive lung cancer development phase
Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.
Why Afrezza’s pediatric FDA approval could reshape mealtime insulin use in children with diabetes
Find out how Afrezza’s pediatric FDA approval could change mealtime insulin use for children with diabetes and MannKind’s growth story.
Can Zaynich help Wockhardt turn Indian antibiotic innovation into a global commercial platform?
Find out how Wockhardt’s Zaynich FDA approval could reshape Indian pharma innovation and the fight against drug-resistant infections.
Can Mycophenolate Mofetil approval strengthen Concord Biotech’s United States generics strategy?
Find out how Concord Biotech’s FDA approval for Mycophenolate Mofetil could reshape its transplant generics strategy.
Zydus gains FDA Priority Review for saroglitazar as PBC treatment competition intensifies
Zydus’ saroglitazar gets FDA Priority Review in PBC, setting up a key test for dual PPAR therapy in rare liver disease.
Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Can Chest Wall Innovations turn FDA clearance into adoption in rib fixation?
Rib fixation is gaining clinical ground. Chest Wall Innovations now faces the harder test: converting FDA clearance into surgeon adoption.
Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.